Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for IXEMPRA KIT
- Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
- Ixabepilone and SBRT For Metastatic Breast Cancer
- A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
- Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
- Ixabepilone + Carboplatin Metastatic Breast Cancer
- A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
- Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
- Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
- Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
- Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
- Ixabepilone to Treat Cervical Cancer
- Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
- Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
- Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
- A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
- FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC
- Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
- Solid Tumors Using Ixabepilone and Dasatinib
- Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
- Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
- Phase 1 Trial of Oral Ixabepilone
- Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
- A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
- A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
- Ixabepilone in Treating Young Patients With Refractory Solid Tumors
- Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
- Ixabepilone Administered as an Enteric Coated Formulation.
- Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
- Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
- Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
- Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Ixabepilone in Treating Patients With Metastatic Prostate Cancer
- Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
- Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
- Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
- BMS-247550 in Treating Patients With Stage IV Melanoma
- Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
- BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
- Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
- BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
- BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
- Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
Clinical trials list
click for details